NewAmsterdam Pharma Newsroom

Express News | Form 144 | NewAmsterdam Pharma(NAMS.US) Insider Proposes to Sell 35.34 Million in Common Stocks

Moomoo NewsJan 10 16:33 ET

NewAmsterdam Pharma Outlines 2025 Strategy With Obicetrapib Focus; Expects EMA Filing In H2 2025, Unveils $835M Year-End Cash. Highlights: BROADWAY 33% LDL-C Reduction, TANDEM 49% Reduction, BROOKLYN 36% Reduction; PREVAIL Trial Ongoing. VINCENT &...

BenzingaJan 10 08:13 ET

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

GlobeNewswireJan 10 08:00 ET

Express News | NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersJan 9 15:38 ET

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireJan 9 15:38 ET

Merck Downgraded by Truist to Hold Over Growth Concerns

Seeking AlphaJan 8 10:19 ET

HC Wainwright & Co. Initiates Coverage On NewAmsterdam Pharma With Buy Rating, Announces Price Target of $48

BenzingaDec 30, 2024 07:03 ET · Ratings

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and NewAmsterdam Pharma Company (NAMS)

TipRanksDec 30, 2024 06:40 ET · Ratings

Express News | NewAmsterdam Pharma Company NV : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $48

ReutersDec 30, 2024 06:13 ET

NewAmsterdam Pharma(NAMS.US) 10% Shareholder Sells US$4.07 Million in Common Stock

Moomoo NewsDec 20, 2024 16:31 ET

Positive Outlook for NewAmsterdam Pharma Driven by Strong Financial Position and Promising Obicetrapib Trial Results

TipRanksDec 20, 2024 12:59 ET

NewAmsterdam Pharma(NAMS.US) 10% Shareholder Sells US$4.86 Million in Common Stock

Moomoo NewsDec 16, 2024 16:20 ET

Menarini Group Announces Positive Topline Data From Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib With Ezetimibe 10 Mg

PR NewswireDec 16, 2024 08:40 ET

Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?

BenzingaDec 15, 2024 10:00 ET

NewAmsterdam Pharma(NAMS.US) 10% Shareholder Sells US$11.74 Million in Common Stock

Moomoo NewsDec 12, 2024 16:18 ET

NewAmsterdam Pharma 12.12M Share Secondary Priced at $24.50

TipRanksDec 11, 2024 21:55 ET

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

GlobeNewswireDec 11, 2024 21:37 ET

NewAmsterdam Pharma Is Maintained at Sector Outperform by Scotiabank

Dow JonesDec 11, 2024 11:23 ET · Ratings

NewAmsterdam Pharma Price Target Raised to $47.00/Share From $35.00 by Scotiabank

Dow JonesDec 11, 2024 11:23 ET · Ratings

NewAmsterdam Pharma Analyst Ratings

BenzingaDec 11, 2024 11:11 ET · Ratings